Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Amplia advances pancreatic cancer trial planning as quarterly cash falls to $21 million

ATX: $0.083 +5.06% · MC: $45M

Amplia said its ACCENT pancreatic cancer trial is nearing completion and it is planning a registrational study, with Australian sites preparing to start the initial stage and a US FDA design meeting planned for the second quarter of 2027. September-quarter operating cash outflows eased to about $3 million from about $4 million in the previous quarter, while cash declined to about $21 million from about $24 million at June-end; a research tax refund received in October lifted the pro forma balance to about $26 million. The company also highlighted its Eli Lilly collaboration to study narmafotinib with an experimental lung cancer drug.

Source announcements: 2026-10-28 08:22 to 2026-10-28 08:22 Sydney time
Story updated 2026-10-28 08:26 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments